Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUR-928 in Moderate and Severe Alcoholic Hepatitis
NCT03917407Phase 2Completed
- Start
- Jun 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of larsucosterol in alcoholic hepatitis (AH) (2 arms). Primary endpoints: Treatment-Emergent Adverse Events at 4.5 years, Model for End-Stage Liver Disease at 33 days and 8 more. Started Jun 2021; status: completed.
02
Drugs
larsucosterol
03
Conditions
alcoholic hepatitis (AH)
Beyond the preview
Go deeper on NCT03917407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03917407.